Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Renub Research | PRODUCT CODE: 1125958

Cover Image

PUBLISHER: Renub Research | PRODUCT CODE: 1125958

United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Excel (Dashboard)
USD 2490
PDF (Single User License)
USD 2990
PDF (5 User License + Excel)
USD 3490
PDF (Corporate License)
USD 3990

Add to Cart

United States Liquid Biopsy Market is expected to reach US$ 803.8 Million by 2027. Liquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumor cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years to develop a less invasive and more precise individualized therapy. Furthermore, due to its sophisticated nature, which includes a short turnaround time and feasibility and the capacity to do early cancer screening, liquid biopsies are becoming more popular in the United States.

United States Liquid Biopsy Market Size is expected to expand at a CAGR of 17.50% during 2021-2027:

The liquid biopsy methods are minimally invasive and cost-effective in the United States. As a result, they are a popular alternative for cancer diagnosis among Americans. Other essential driving factors influencing the US liquid biopsy market in the projected period include an increase in patient demand for non-invasive treatment procedures and the number of cancer patients. However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.

How COVID-19 Affected United States Liquid Biopsy Industry:

The coronavirus outbreak damaged the US biopsy diagnostics centers, hospitals, supply chains, and clinical trials. As a result, cancer diagnoses were being delayed since clinics had been closed since the start of the COVID-19 pandemic, and diagnosis and screening services were growing slower. In addition, cancer patients had numerous obstacles outside of the pandemic, including increased susceptibility to severe infection and disruptions in treatment or routine medical care. According to our estimates, the United States Liquid Biopsy Market reached US$ 305.4 Million in 2021 post recovery from the pandemic scenario.

Lung Cancer Accounts for The Dominant Market Share in The Forecast Period:

The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer. Lung cancer is expected to have the largest market share during the projection period. According to the American Cancer Society, non-small-cell lung cancer, the most frequent kind of lung cancer in the United States, will be diagnosed in 235,760 persons in 2021. Lung cancer affects one in every 17 men and one in every 15 women at some point in their lives.

By Product, Assay Kits Holds the Largest Market Share:

The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services. Thekits and consumablesare expected to have the most significant market share during the projection period. In the projection period, demand for kits and consumableswill be driven by the ability to repeat sampling for liquid biopsy and their convenience and affordability.

Circulating Tumor Cells Maintains Their Dominance:

The liquid biopsy market in the United States is classified into Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs), and Other biomarkers based on the circulating biomarker (cell-free DNA, etc.). Circular tumor cells are expected to maintain their dominance throughout the predicted period. The market demand for Circulating tumor DNA is being driven by the rising frequency of cancer and the introduction of ctDNA-based liquid biopsy analysis, which can evaluate prognosis and tumor progression (ctDNA).

Other Segment Covered in Our Report Includes the Following:

Based on clinical application, the market has been segmented into monitoring, prognosis, theranostics, and screening.

In addition, the market has been segmented into blood, urine, and others based on a sample.

Finally, based on application, the market has been segmented into molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS.

The market has been segmented into hospitals and laboratories and government & academic research centers based on end-user.

Key Companies Insights:

Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc, and Qiagen are among the important players profiled in our report. These market players in the United States contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.

Renub Research latest report "United States Liquid Biopsy Market, Forecast By Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others), By Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating tumor cell (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs) and Other biomarkers (cell free DNA,etc)), Clinical Application (Monitoring, Prognosis, Theranostics and Screening), Sample (Blood, Urine and Others), Application (Molecular Health Monitoring, Therapy Selection for Other Meta Cancer and Therapy Selection for MBS), End User (Hospitals and Laboratories and Government & Academic Research Centers), Companies (Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen)" provides a detailed analysis of United States Liquid Biopsy Industry.

By Cancer, the Market has been segmented into 5 viewpoints:

1. Lung Cancer

2. Breast Cancer

3. Colorectal Cancer

4. Prostate Cancer

5. Others

By Product the Market has been segmented into 3 viewpoints:

1. Kits & Consumables

2. Instruments

3. Services

By Circulating Biomarkers, the market has been segmented into 4 viewpoints:

1. Circulating tumor cell (CTCs)

2. Circulating tumor DNA (ctDNA)

3. Extracellular vesicles (EVs)

4. Other biomarkers (cell free DNA,etc)

By Clinical Application the market has been segmented into 4 viewpoints:

1. Monitoring

2. Prognosis

3. Theranostics

4. Screening

By Sample the market has been segmented into 3 viewpoints:

1. Blood

2. Urine

3. Others

By Application, the market has been segmented into 3 viewpoints:

1. Molecular Health Monitoring

2. Therapy Selection for Other Meta Cancer

3. Therapy Selection for MBS

By End User, the market has been segmented from 2 viewpoints:

1. Hospitals and Laboratories

2. Government & Academic Research Centers

Company Insights:

  • Overview
  • Product Portfolio
  • Financial Insight

Companies Covered:

1. Thermo Fisher Scientific Inc

2. Roche Diagnostics

3. Bio-Rad Laboratories Inc

4. Biocept, Inc.

5. Biocartis

6. Myriad Genetics, Inc.

7. Exact Sciences (Genomic Health)

8. NeoGenomics Laboratories

9. Quest Diagnostic Inc

10. Qiagen

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. United States Liquid Biopsy Market

6. Market Share - United States Liquid Biopsy

  • 6.1 By Cancer
  • 6.2 By Product
  • 6.3 By Circulating Biomarkers
  • 6.4 By Clinical Application
  • 6.6 By Application
  • 6.7 By End User

7. Cancer - United States Liquid Biopsy Market

  • 7.1 Lung Cancer
  • 7.2 Breast Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Prostate Cancer
  • 7.6 Others

8. Product - United States Liquid Biopsy Market

  • 8.1 Kits & Consumables
  • 8.2 Instruments
  • 8.3 Services

9. Circulating Biomarkers - United States Liquid Biopsy Market

  • 9.1 Circulating tumor cell (CTCs)
  • 9.2 Circulating tumor DNA (ctDNA)
  • 9.3 Extracellular vesicles (EVs)
  • 9.4 Other biomarkers (cell free DNA,etc)

10. Clinical Application - United States Liquid Biopsy Market

  • 10.1 Monitoring
  • 10.2 Prognosis
  • 10.3 Theranostics
  • 10.4 Screening

11. Sample - United States Liquid Biopsy Market

  • 11.1 Blood
  • 11.2 Urine
  • 11.3 Others

12. Application - United States Liquid Biopsy Market

  • 12.1 Molecular Health Monitoring
  • 12.2 Therapy Selection for Other Meta Cancer
  • 12.3 Therapy Selection for MBS

13. End User - United States Liquid Biopsy Market

  • 13.1 Hospitals and Laboratories
  • 13.2 Government & Academic Research Centers

14. Company Analysis

  • 14.1 Thermo Fisher Scientific Inc
    • 14.1.1 Overview
    • 14.1.2 Product Portfolio
    • 14.1.3 Financial Insight
  • 14.2 Roche Diagnostics
    • 14.2.1 Overview
    • 14.2.2 Product Portfolio
    • 14.2.3 Financial Insight
  • 14.3 Bio-Rad Laboratories Inc
    • 14.3.1 Overview
    • 14.3.2 Product Portfolio
    • 14.3.3 Financial Insight
  • 14.4 Biocept, Inc.
    • 14.4.1 Overview
    • 14.4.2 Product Portfolio
    • 14.4.3 Financial Insight
  • 14.5 Biocartis
    • 14.5.1 Overview
    • 14.5.2 Product Portfolio
    • 14.5.3 Financial Insight
  • 14.6 Myriad Genetics, Inc
    • 14.6.1 Overview
    • 14.6.2 Product Portfolio
    • 14.6.3 Financial Insight
  • 14.7 Exact Sciences (Genomic Health)
    • 14.7.1 Overview
    • 14.7.2 Product Portfolio
    • 14.7.3 Financial Insight
  • 14.8 NeoGenomics Laboratories
    • 14.8.1 Overview
    • 14.8.2 Product Portfolio
    • 14.8.3 Financial Insight
  • 14.9 Quest Diagnostic Inc
    • 14.9.1 Overview
    • 14.9.2 Product Portfolio
    • 14.9.3 Financial Insight
  • 14.10 Qiagen
    • 14.10.1 Overview
    • 14.10.2 Product Portfolio
    • 14.10.3 Financial Insight

List of Figures

  • Figure-01: United States - Liquid Biopsy Market (Million US$), 2017 - 2021
  • Figure-02: United States - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-03: United States - Lung Cancer Market (Million US$), 2017 - 2021
  • Figure-04: United States - Forecast for Lung Cancer Market (Million US$), 2022 - 2027
  • Figure-05: United States - Breast Cancer Market (Million US$), 2017 - 2021
  • Figure-06: United States - Forecast for Breast Cancer Market (Million US$), 2022 - 2027
  • Figure-07: United States - Colorectal Cancer Market (Million US$), 2017 - 2021
  • Figure-08: United States - Forecast for Colorectal Cancer Market (Million US$), 2022 - 2027
  • Figure-09: United States - Prostate Cancer Market (Million US$), 2017 - 2021
  • Figure-10: United States - Forecast for Prostate Cancer Market (Million US$), 2022 - 2027
  • Figure-11: United States - Others Market (Million US$), 2017 - 2021
  • Figure-12: United States - Forecast for Others Market (Million US$), 2022 - 2027
  • Figure-13: Product - Kits & Consumables Market (Million US$), 2017 - 2021
  • Figure-14: Product - Forecast for Kits & Consumables Market (Million US$), 2022 - 2027
  • Figure-15: Product - Instruments Market (Million US$), 2017 - 2021
  • Figure-16: Product - Forecast for Instruments Market (Million US$), 2022 - 2027
  • Figure-17: Product - Services Market (Million US$), 2017 - 2021
  • Figure-18: Product - Forecast for Services Market (Million US$), 2022 - 2027
  • Figure-19: Circulating Biomarkers - Circulating tumor cell (CTCs) Market (Million US$), 2017 - 2021
  • Figure-20: Circulating Biomarkers - Forecast for Circulating tumor cell (CTCs) Market (Million US$), 2022 - 2027
  • Figure-21: Circulating Biomarkers - Circulating tumor DNA (ctDNA) Market (Million US$), 2017 - 2021
  • Figure-22: Circulating Biomarkers - Forecast for Circulating tumor DNA (ctDNA) Market (Million US$), 2022 - 2027
  • Figure-23: Circulating Biomarkers - Extracellular vesicles (EVs) Market (Million US$), 2017 - 2021
  • Figure-24: Circulating Biomarkers - Forecast for Extracellular vesicles (EVs) Market (Million US$), 2022 - 2027
  • Figure-25: Circulating Biomarkers - Other biomarkers (cell free DNA,etc) Market (Million US$), 2017 - 2021
  • Figure-26: Circulating Biomarkers - Forecast for Other biomarkers (cell free DNA,etc) Market (Million US$), 2022 - 2027
  • Figure-27: Clinical Application - Monitoring Market (Million US$), 2017 - 2021
  • Figure-28: Clinical Application - Forecast for Monitoring Market (Million US$), 2022 - 2027
  • Figure-29: Clinical Application - Prognosis Market (Million US$), 2017 - 2021
  • Figure-30: Clinical Application - Forecast for Prognosis Market (Million US$), 2022 - 2027
  • Figure-31: Clinical Application - Theranostics Market (Million US$), 2017 - 2021
  • Figure-32: Clinical Application - Forecast for Theranostics Market (Million US$), 2022 - 2027
  • Figure-33: Clinical Application - Screening Market (Million US$), 2017 - 2021
  • Figure-34: Clinical Application - Forecast for Screening Market (Million US$), 2022 - 2027
  • Figure-35: Sample - Blood Market (Million US$), 2017 - 2021
  • Figure-36: Sample - Forecast for Blood Market (Million US$), 2022 - 2027
  • Figure-37: Sample - Urine Market (Million US$), 2017 - 2021
  • Figure-38: Sample - Forecast for Urine Market (Million US$), 2022 - 2027
  • Figure-39: Sample - Others Market (Million US$), 2017 - 2021
  • Figure-40: Sample - Forecast for Others Market (Million US$), 2022 - 2027
  • Figure-41: Application - Molecular Health Monitoring Market (Million US$), 2017 - 2021
  • Figure-42: Application - Forecast for Molecular Health Monitoring Market (Million US$), 2022 - 2027
  • Figure-43: Application - Therapy Selection for Other Meta Cancer Market (Million US$), 2017 - 2021
  • Figure-44: Application - Forecast for Therapy Selection for Other Meta Cancer Market (Million US$), 2022 - 2027
  • Figure-45: Application - Therapy Selection for MBS Market (Million US$), 2017 - 2021
  • Figure-46: Application - Forecast for Therapy Selection for MBS Market (Million US$), 2022 - 2027
  • Figure-47: End User - Hospitals and Laboratories Market (Million US$), 2017 - 2021
  • Figure-48: End User - Forecast for Hospitals and Laboratories Market (Million US$), 2022 - 2027
  • Figure-49: End User - Government & Academic Research Centers Market (Million US$), 2017 - 2021
  • Figure-50: End User - Forecast for Government & Academic Research Centers Market (Million US$), 2022 - 2027
  • Figure-51: Thermo Fisher Scientific Inc - Global Revenue (Million US$), 2017 - 2021
  • Figure-52: Thermo Fisher Scientific Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-53: Roche Diagnostics - Global Revenue (Million US$), 2017 - 2021
  • Figure-54: Roche Diagnostics - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-55: Bio-Rad Laboratories Inc - Global Revenue (Million US$), 2017 - 2021
  • Figure-56: Bio-Rad Laboratories Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-57: Biocept, Inc. - Global Revenue (Million US$), 2017 - 2021
  • Figure-58: Biocept, Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-59: Biocartis - Global Revenue (Million US$), 2017 - 2021
  • Figure-60: Biocartis - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-61: Myriad Genetics, Inc - Global Revenue (Million US$), 2017 - 2021
  • Figure-62: Myriad Genetics, Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-63: Exact Sciences (Genomic Health) - Global Revenue (Million US$), 2017 - 2021
  • Figure-64: Exact Sciences (Genomic Health) - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-65: NeoGenomics Laboratories - Global Revenue (Million US$), 2017 - 2021
  • Figure-66: NeoGenomics Laboratories - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-67: Quest Diagnostic Inc - Global Revenue (Million US$), 2017 - 2021
  • Figure-68: Quest Diagnostic Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-69: Qiagen - Global Revenue (Million US$), 2017 - 2021
  • Figure-70: Qiagen - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

  • Table-01: United States - Liquid Biopsy Market Share by Cancer (Percent), 2017 - 2021
  • Table-02: United States - Forecast for Liquid Biopsy Market Share by Cancer (Percent), 2022 - 2027
  • Table-03: United States - Liquid Biopsy Market Share by Product (Percent), 2017 - 2021
  • Table-04: United States - Forecast for Liquid Biopsy Market Share by Product (Percent), 2022 - 2027
  • Table-05: United States - Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2017 - 2021
  • Table-06: United States - Forecast for Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2022 - 2027
  • Table-07: United States - Liquid Biopsy Market Share by Clinical Application (Percent), 2017 - 2021
  • Table-08: United States - Forecast for Liquid Biopsy Market Share by Clinical Application (Percent), 2022 - 2027
  • Table-09: United States - Liquid Biopsy Market Share by Application (Percent), 2017 - 2021
  • Table-10: United States - Forecast for Liquid Biopsy Market Share by Application (Percent), 2022 - 2027
  • Table-11: United States - Liquid Biopsy Market Share by End User (Percent), 2017 - 2021
  • Table-12: United States - Forecast for Liquid Biopsy Market Share by End User (Percent), 2022 - 2027
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!